Yu, Ming-Lung <br/><br/>
A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan.  [electronic resource] 

 -  Liver international : official journal of the International Association for the Study of the Liver  Feb 2006 
 - 73-81 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1478-3223 
<br/><br/><label>Standard No.: </label>10.1111/j.1478-3231.2005.01196.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antiviral Agents--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Follow-Up Studies<br/>Genotype<br/>Hepacivirus--genetics<br/>Hepatitis C, Chronic--diagnosis<br/>Humans<br/>Interferon alpha-2<br/>Interferon-alpha--administration & dosage<br/>Liver Function Tests<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Pilot Projects<br/>Polyethylene Glycols<br/>Probability<br/>ROC Curve<br/>Recombinant Proteins<br/>Reference Values<br/>Ribavirin--administration & dosage<br/>Risk Assessment<br/>Severity of Illness Index<br/>Single-Blind Method<br/>Taiwan<br/>Treatment Outcome